Gravity Analytica

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BPMC 12.18.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our BPMC Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.,Dec. 18, 2024/PRNewswire/ --Blueprint Medicines Corporation(Nasdaq: BPMC) today announced thatKate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43^rdAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 13, 2025, at9:00 a.m. PT(12:00 p.m. ET).

A live webcast of the presentation will be available by visiting the Investors & Media section ofBlueprint Medicines'website athttp://ir.blueprintmedicines.com. A replay of the webcast will be archived onBlueprint Medicines'website for 30 days following the presentation.

AboutBlueprint Medicines

Blueprint Medicinesis a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT^®/AYVAKYT^®(avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in theU.S.andEurope. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visitwww.BlueprintMedicines.comand follow us onX(formerly Twitter; @BlueprintMeds) andLinkedIn.

Trademarks

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334060.html

SOURCEBlueprint Medicines Corporation

Investor Contact, Cassie Saitow, +1 (617) 909-3127, ir@blueprintmedicines.com; Media Contact, Andrew Law, +1 (617) 844-8205, media@blueprintmedicines.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com